Living lung model: A breath of fresh air for personalized treatment

University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...

Inhaled RNA therapy cuts lung inflammation after severe infections in preclinical tests

NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
YourTango

I Had Warning Signs For Years, But It Took A Heart Attack To Reveal The Rare Genetic Disease Doctors Missed

For years, father of two Peter Martini experienced subtle symptoms that never seemed serious enough to raise alarm, but in ...
The Manila Times

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
News-Medical.Net

NTU Singapore and partners develop new inhaled treatment for severe lung infections

Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB ...